BNGO — BioNano Genomics Cashflow Statement
0.000.00%
Last trade - 00:00- $13.31m
- -$2.23m
- $28.51m
Annual cashflow statement for BioNano Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -72.4 | -133 | -232 | -112 | -26.4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 10.6 | 24.8 | 90.9 | 30.7 | 4.96 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.65 | -28.6 | 2.48 | -1.83 | -4.64 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -71.9 | -125 | -125 | -68.9 | -16.3 |
| Capital Expenditures | -0.822 | -2.41 | -1.69 | -0.103 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -277 | 85.2 | 25.8 | 73.9 | -12.7 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -278 | 82.8 | 24.2 | 73.8 | -12.7 |
| Financing Cash Flow Items | -1.7 | -0.428 | -14.9 | -10.1 | -2.12 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 336 | 23 | 114 | -13.7 | 24 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -13.9 | -19.1 | 12.9 | -8.78 | -5.06 |